Global News

Chiltern promotes Stuart McGuire and Jim Szymeczek

Thursday, March 28, 2013 08:00 AM

Chiltern International, a global contract CRO, has promoted Stuart McGuire to the position of vice president of global business development, and Jim Szymeczek to the position of vice president of global information technology and systems.

More... »

BioDelivery Sciences acquires topical clonidine gel for painful diabetic neuropathy

Wednesday, March 27, 2013 11:53 AM

BioDelivery Sciences International (BDSI) has entered into a worldwide licensing agreement with privately held Arcion Therapeutics, where BDSI will develop and commercialize topical clonidine gel (formerly ARC4558) for the treatment of painful diabetic neuropathy (PDN) and potentially other indications. 

More... »

Lundbeck, Otsuka expand alliance, plan to development Lu AE58054 for Alzheimer's

Wednesday, March 27, 2013 11:24 AM

Global pharmaceutical company H. Lundbeck and global healthcare company Otsuka Pharmaceutical have formed a license and development agreement for Lu AE58054, a selective 5HT6 receptor antagonist currently in development for the treatment of Alzheimer's disease.

More... »

Actavis to expand Florida manufacturing facility, create 220 jobs

Wednesday, March 27, 2013 10:55 AM

Actavis, a specialty pharmaceutical company formerly known as Watson Pharmaceuticals, plans to expand its pharmaceutical manufacturing and warehousing facilities in Davie, Fla., resulting in the creation of 220 jobs.

More... »

PrimeraDx, Quest Diagnostics to develop companion diagnostics

Wednesday, March 27, 2013 10:26 AM

PrimeraDx, a molecular diagnostics company, has formed a non-exclusive diagnostics co-development agreement with Quest Diagnostics, a diagnostics information services company. The intent of the collaboration is to co-develop and commercialize molecular diagnostic products and services with a focus on supporting clinical development of targeted therapeutics for drug developers.

More... »

Ziopharm terminates development of palifosfamide in metastatic soft tissue sarcoma

Wednesday, March 27, 2013 09:57 AM

Ziopharm Oncology, a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced that its phase III trial of palifosfamide (ZIO-201) for the treatment of metastatic soft tissue sarcoma in the first-line setting (PICASSO 3) did not meet its primary endpoint of progression-free survival (PFS).

More... »

Spinifex receives $1.5M in R&D tax incentive relating to pain research

Wednesday, March 27, 2013 09:28 AM

Spinifex Pharmaceuticals, an Australian pain drug development company, has received an approximately $1.5 million R&D tax incentives cash refund for research activities relating to the discovery of new drugs for the treatment and management of pain.

More... »

PPD appoints Jay Dixon as vice president, global quality and compliance

Tuesday, March 26, 2013 08:00 AM

Pharmaceutical Product Development (PPD), a global CRO, has appointed Jay Dixon as senior vice president, global quality and compliance. Dixon’s expertise will enhance PPD’s ability to deliver industry-leading drug development services and high-quality data across the full spectrum of the research and development life cycle.

More... »

Survey underscores importance of patient education and engagement in personalized medicine

Monday, March 25, 2013 02:17 PM

Nearly two out of three people in four major European countries have no awareness of personalized medicine—despite the fact that this evolving discipline has vast implications for Europe's healthcare issues and Europeans' personal health.

More... »

BBK Worldwide expands ownership from within

Monday, March 25, 2013 01:47 PM

In an industry increasingly defined by mergers and acquisitions, BBK Worldwide is bucking the trend by creating ownership opportunities from within.

More... »